An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ...

An expert discusses the importance of balancing efficacy with safety in ITP treatment, emphasizing cautious use of steroids, close monitoring of therapy-related side effects, and maintaining platelet ...

The addition of ianalumab to eltrombopag significantly prolonged the duration of safe platelet levels. Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in ...

ITP (immune thrombocytopenia) is an autoimmune disorder where the body attacks its own blood platelets. This leads to a decrease in the number of platelets and consequently can cause a number of ...

Amgen Inc. has announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nplate™ (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia ...

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, conducted a multicenter comprehensive retrospective analysis to assess the ...

Severe thrombocytopenia can be very dangerous, even fatal, without treatment. Treatment depends on the underlying cause but can include medications, transfusions, and surgery. Severe thrombocytopenia ...

Mild thrombocytopenia is a condition marked by a low platelet count. Many people experience no symptoms, and the condition resolves on its own. Treatment, if needed, depends on the underlying cause.

Thrombotic thrombocytopenic purpura (TTP) and immune thrombocytopenia (ITP) are both blood disorders that affect blood clotting. TTP is more serious than ITP. The term “thrombocytopenia” refers to low ...